Fuso Pharmaceutical Industries Breaks Up Development Of Cytosine Deaminase Gene Expression Adenovirus Vector

Published: Jan 06, 2004

Fuso Pharmaceutical (TSE: 4538) has conducted research of the vector for gene therapy of cancer with GenVec. However, due to the fact that this research has become out of date, a decision was made to stop the development. The company intends to concentrate efforts on creating safer and more specialized vectors for the cancer cell.

Back to news